tiprankstipranks
Syndax Pharmaceuticals Inc (SNDX)
NASDAQ:SNDX

Syndax Pharmaceuticals Stock Price & Analysis

418 Followers

SNDX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$13.27 - $25.71
Previous Close$24.95
Volume661.28K
Average Volume (3M)640.48K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$170.16M
Total Debt (Recent Filing)$12.15M
P/E Ratio130.2
Beta0.57
Next EarningsNov 07, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)0.19
Shares Outstanding56,565,165
R-Squared0.09
Standard Deviation0.20
10 Day Avg. Volume593,202
30 Day Avg. Volume640,479
P/B Ratio3.77
P/S Ratio11.15
P/CF Ratio137.60
P/FCF Ratio74.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside29.26% Upside
Rating ConsensusStrong Buy
Alpha0.02
Number of Analyst Covering4


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

SNDX FAQ

What was Syndax Pharmaceuticals’s price range in the past 12 months?
Syndax Pharmaceuticals lowest stock price was $13.27 and its highest was $25.71 in the past 12 months.
    What is Syndax Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Syndax Pharmaceuticals’s upcoming earnings report date?
    Syndax Pharmaceuticals’s upcoming earnings report date is Nov 07, 2022 which is in 33 days.
      How were Syndax Pharmaceuticals’s earnings last quarter?
      Syndax Pharmaceuticals released its earnings results on Aug 08, 2022. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$0.637 by $0.017.
        Is Syndax Pharmaceuticals overvalued?
        According to Wall Street analysts Syndax Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Syndax Pharmaceuticals pay dividends?
          Syndax Pharmaceuticals does not currently pay dividends.
          What is Syndax Pharmaceuticals’s EPS estimate?
          Syndax Pharmaceuticals’s EPS estimate is -$0.64.
            How many shares outstanding does Syndax Pharmaceuticals have?
            Syndax Pharmaceuticals has 56,565,166 shares outstanding.
              What happened to Syndax Pharmaceuticals’s price movement after its last earnings report?
              Syndax Pharmaceuticals reported an EPS of -$0.62 in its last earnings report, beating expectations of -$0.637. Following the earnings report the stock price went down -1.194%.
                Which hedge fund is a major shareholder of Syndax Pharmaceuticals?
                Among the largest hedge funds holding Syndax Pharmaceuticals’s share is Deerfield Management Company, LP. It holds Syndax Pharmaceuticals’s shares valued at 21M.

                  ---

                  Syndax Pharmaceuticals Stock Analysis

                  Smart ScoreOutperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  9
                  The Syndax Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Syndax Pharmaceuticals Inc

                  Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  AbbVie
                  Amgen
                  Gilead Sciences
                  Moderna
                  Vertex Pharmaceuticals

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis